Ramon Lee, MD
Retina Specialist · Royal Oak, MINPI 1194119339
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Regeneron at 44.5% of the total. Reporting peaked in 2024 at $11,217 and has fallen 73.8% since, to $2,933 in 2025.
Across 108 payments — averaging $173.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$8K
- Bausch & Lomb Americas Inc.$4K
- Alimera Sciences, Inc.$2K
- Astellas Pharma US Inc$522
- Regeneron Healthcare Solutions, Inc.$424
- Novartis$383
- plus $3K from 17 others
What the payments were for
- Consulting fees$8,02043%
- Speaking & faculty fees$5,59630%
- Travel & lodging$4602%
- Food & beverage$4,64425%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 11 | $8,322 |
| Bausch & Lomb Americas Inc. | 2 | $4,000 |
| Alimera Sciences, Inc. | 8 | $2,042 |
| Astellas Pharma US Inc | 8 | $522 |
| Regeneron Healthcare Solutions, Inc. | 12 | $424 |
| Novartis | 9 | $383 |
| AbbVie(2 entities) | 13 | $357 |
| Thea Pharma Inc. | 1 | $350 |
| Abbott | 5 | $339 |
| Genentech USA, Inc. | 5 | $332 |
| Alcon | 3 | $296 |
| Apellis Pharmaceuticals, Inc. | 7 | $290 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $250 |
| Coherus Oncology, Inc. | 6 | $162 |
| Cardinal Health 110 LLC | 1 | $150 |
| Philips North America LLC | 3 | $123 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $98 |
| Eyepoint US, Inc. | 3 | $72 |
| Sandoz | 2 | $56 |
| Notal Vision, Inc. | 1 | $46 |
| Amgen | 2 | $44 |
| Shockwave Medical, Inc | 2 | $32 |
| Heartflow, Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,720 in reported general payments places this provider in the 75th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 144 | $5,312 |
| Atropine Sulfate | 33 | $1,004 |
| Gatifloxacin | 20 | $561 |
| Brimonidine Tartrate | 51 | $468 |
| Ketorolac Tromethamine | 38 | $457 |
| MoxifloxacinMoxifloxacin Hcl | 16 | $234 |
| Timolol Maleate | 19 | $229 |
| Latanoprost | 14 | $191 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $178 |
| Dorzolamide Hcl | 14 | $128 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Royal Oak
- Jeremy WolfeRoyal Oak$809K
- Lisa FaiaRoyal Oak$520K
- Tarek HassanRoyal Oak$460K
- Sandeep RandhawaRoyal Oak$94K
- Kimberly DrenserRoyal Oak$79K
- Adam WeinerRoyal Oak$31K
- Michael TreseRoyal Oak$26K
- Antonio CaponeRoyal Oak$20K
- Jong ParkRoyal Oak$12K
- Tianyu LiuRoyal Oak$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.